Bioanalytical assays for gene therapy programs: an interview with Catherine Vrentas

Cell and gene therapies Interviews

In this podcast interview, Catherine (Cathy) Vrentas of PPD® Laboratory services, a part of Thermo Fisher Scientific (VA, USA) discusses how to leverage bioanalytical assays for gene therapy programs, key considerations in the development of these assays and how the unique nature of gene therapies impacts the development and maintenance of bioanalytical assays.

Questions

1. What are some of the types of bioanalytical assays important for gene therapy programs?
2. What are some of the key questions regarding the design of quantitative assays for gene therapy?
3. How does the unique nature of gene therapies—specifically regarding the nature of the reference material—impact development and long-term maintenance of assays, especially enzymatic assays?
4. What are some of the key considerations inherent to development of assays to assess levels of analytes in tissues?

In association with: